Boundless Bio, Inc. Common Stock - Asset Resilience Ratio
Boundless Bio, Inc. Common Stock (BOLD) has an Asset Resilience Ratio of 60.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Boundless Bio, Inc. Common Stock's Asset Resilience Ratio has changed over time. See Boundless Bio, Inc. Common Stock financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Boundless Bio, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Boundless Bio, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $102.59 Million | 60.8% |
| Total Liquid Assets | $102.59 Million | 60.80% |
Asset Resilience Insights
- Very High Liquidity: Boundless Bio, Inc. Common Stock maintains exceptional liquid asset reserves at 60.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Boundless Bio, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Boundless Bio, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Boundless Bio, Inc. Common Stock (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Boundless Bio, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 60.81% | $125.53 Million | $206.41 Million | -13.90pp |
| 2023-12-31 | 74.71% | $97.05 Million | $129.89 Million | +2.13pp |
| 2022-12-31 | 72.58% | $55.77 Million | $76.83 Million | +38.51pp |
| 2021-12-31 | 34.07% | $38.74 Million | $113.72 Million | -23.06pp |
| 2018-12-31 | 57.13% | $269.96 Million | $472.56 Million | +4.16pp |
| 2017-12-31 | 52.97% | $94.64 Million | $178.66 Million | +4.73pp |
| 2016-12-31 | 48.24% | $68.52 Million | $142.06 Million | -- |
About Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene ampli… Read more